Insulinoma Clinical Trial
Official title:
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
The purpose of this study is to compare the clinical efficacy and economic cost of enucleation after placement of pancreatic duct stents before surgery with that of direct enucleation alone, and to evaluate its safety and feasibility.
The research contents of this study include: patients with insulinoma near the main pancreatic duct in the head and neck of the pancreas were randomly divided into two groups: the preoperative pancreatic duct stent enucleation group (stended EN), the direct en group (DEN), the Sen group asked a digestive endoscopist to place the pancreatic duct stent before surgery, and the next day or the next day after surgery, and the den group received enucleation directly. The safety of the two groups was compared, including the evaluation of surgical effect Postoperative complications and long-term prognosis based on follow-up data analysis; At the same time, the differences between the two groups were evaluated from the perspective of health economics. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
Withdrawn |
NCT02108782 -
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT05034783 -
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
|
Early Phase 1 | |
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
Recruiting |
NCT04185350 -
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
|
Early Phase 1 | |
Recruiting |
NCT00001276 -
Diagnosing and Treating Low Blood Sugar Levels
|
||
Active, not recruiting |
NCT02121366 -
EUS-guided Ethanol Ablation of an Insulinoma
|
N/A | |
Terminated |
NCT00084461 -
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00131911 -
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00005910 -
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
|
N/A | |
Recruiting |
NCT03583528 -
DOTATOC PET/CT for Imaging NET Patients
|
||
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT02560376 -
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
|
Phase 0 | |
Completed |
NCT01525082 -
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00655655 -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00075439 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A | |
Active, not recruiting |
NCT01824875 -
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |